The US Food and Drug Administration (FDA) has granted accelerated approval to Zegfrovy (sunvozertinib) for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC ...

The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

Adding atezolizumab and bevacizumab to TACE can improve outcomes in previously untreated, unresectable HCC, data suggest.

Provisions in the new tax and spending bill passed by the Senate would go even further than the House bill in removing health care and other benefits from immigrants with legal status.

Breast cancer patients may have inferior recurrence-free survival after neoadjuvant chemotherapy if they are overweight or obese at diagnosis.

Provisions in the new tax and spending bill passed by the Senate would go even further than the House bill in removing health ...

Waiting about 9 months or more to rechallenge patients with amivantamab can improve outcomes in patients with colorectal cancer, data suggest.

Cuts that would target states could translate into fewer health services, medical professionals, and even hospitals, especially in rural communities.

Uterine cancer cases and deaths are projected to increase in Black women and White women in the United States.

Breast cancer survivors have a lower risk of Alzheimer's disease than cancer-free control individuals, data suggest.

President Donald Trump’s “One Big Beautiful Bill” cuts federal spending on Medicaid and Affordable Care Act marketplaces by about $1 trillion over a decade, according to the nonpartisan Congressional ...

Results of a meta-analysis suggest that ctDNA positivity is a “biomarker for poor postoperative recurrence and survival outcomes in NSCLC patients,” researchers wrote.